Somavaratan

Summary

Somavaratan (CHEMBL3707323) is a phase-3 clinical-stage protein; indicated across 1 condition including pituitary dwarfism.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707323
Name	Somavaratan
Type	Protein
Max phase	3

Also known as: Somavaratan, VRS-317, SOMAVARATAN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pituitary dwarfism	3	MONDO:0006909	EFO:1001109

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2/PHASE3	2
PHASE3	2
PHASE2	2
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02068521	PHASE2/PHASE3	TERMINATED	Versartis Long-Term Safety Study of Somavaratan
NCT02339090	PHASE3	COMPLETED	Long-Acting Growth Hormone in Children Compared to Daily rhGH
NCT02413138	PHASE2/PHASE3	TERMINATED	Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)
NCT03145831	PHASE3	TERMINATED	A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency
NCT01718041	PHASE1/PHASE2	COMPLETED	Versartis Trial in Children to Assess Long-Acting Growth Hormone
NCT02526420	PHASE2	COMPLETED	Versartis International Trial in Adults With Long-Acting Growth Hormone
NCT02719990	PHASE2	TERMINATED	Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)
NCT01359488	PHASE1	COMPLETED	VRS-317 in Adult Subjects With Growth Hormone Deficiency

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).